Stocks and Investing Stocks and Investing
Tue, October 4, 2022
Mon, October 3, 2022
Sun, October 2, 2022
Fri, September 30, 2022
Thu, September 29, 2022
Wed, September 28, 2022

Brian Abrahams Maintained (BIIB) at Buy with Increased Target to $321 on, Sep 28th, 2022


Published on 2024-10-27 23:08:01 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $251 to $321 on, Sep 28th, 2022.

Brian has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Decreased Target to $223 on, Monday, September 12th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, July 21st, 2022


These are the ratings of the 4 analyists that currently disagree with Brian


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $265 on, Thursday, September 22nd, 2022
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022